Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: H4 receptor antagonists are potential novel treatments for inflammatory skin diseases, including atopic dermatitis (AD). Objective: We sought to study the efficacy and safety of ZPL‐3893787 (a selective H4 receptor antagonist) in patients with moderate‐to‐severe AD. Methods: A randomized, double‐blind, placebo‐controlled, parallel‐group study was conducted to evaluate ZPL‐3893787 (30 mg) once‐daily oral therapy in adults with moderate‐to‐severe AD. Patients were randomized (2:1) to ZPL‐3893787 (n = 65) or placebo (n = 33) for 8 weeks. Patients had a history of AD for more than 12 months, Eczema Area and Severity Index (EASI) scores of 12 or greater and 48 or less, Investigator's Global Assessment (IGA) scores of 3 or greater, pruritus scores of 5 or greater (0‐ to 10‐point scale), and AD on 10% or greater of body surface area. Efficacy parameters included EASI, IGA, SCORAD, and pruritus assessment. Results: Treatment with oral ZPL‐3893787 showed a 50% reduction in EASI score compared with 27% for placebo. The placebo‐adjusted reduction in EASI score at week 8 was 5.1 (1‐sided P = .01). Clear or almost‐clear IGA scores were 18.5% with ZPL‐3893787 versus 9.1% with placebo. SCORAD scores exhibited 41% reduction with ZPL‐3893787 versus 26% with placebo (placebo‐adjusted reduction of 10.0, P = .004). There was a 3‐point reduction (scale, 1‐10) in pruritus with ZPL‐3893787, but there was a similar reduction with placebo, resulting in a nonsignificant difference (P = .249). Patient‐reported pruritus subscores obtained from SCORAD were reduced with ZPL‐3893787 compared with placebo at week 8 (nonsignificant). ZPL‐3893787 was well tolerated. Conclusion: For the first time, these results showed that ZPL‐3893787 improved inflammatory skin lesions in patients with AD, confirming H4 receptor antagonism as a novel therapeutic option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Eichenfield, L. F., Ahluwalia, J., Waldman, A., Borok, J., Udkoff, J., & Boguniewicz, M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.009 · Cited by 204
Cited by
Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Self-citationPhysiology and Pathophysiology of Itch
Cevikbas, F., & Lerner, E. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00017.2019 · Cited by 282
Update on the Pathogenesis and Therapy of Atopic Dermatitis
Li, H., Zhang, Z., Zhang, H., Guo, Y., & Yao, Z. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08880-3 · Cited by 277
“It is noteworthy that a 3-point reduction (scale, 1–10) in pruritus occurred with oral ZPL-3893787 versus a similar reduction with placebo [111].”
Itch in Atopic Dermatitis – What Is New?
Legat, F. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644760 · Cited by 82
New and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
Metadata
- Authors
- Werfel, T., Layton, G., Yeadon, M., Whitlock, L., Osterloh, I., Jimenez, P., Liu, W., Lynch, V., Asher, A., Tsianakas, A., & Purkins, L.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 143
- Issue
- 5
- Pages
- 1830-1837.e4
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2900407403
- Cited by
- 139
- References
- 3
- FWCI
- 18.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.